ESR1, PGR, BCL2 AND SCUBE2 GROUP SCORE AS INDICATORS OF BREAST CANCER PROGNOSIS AND PREDICTION OF TREATMENT RESPONSE

摘要

The present invention relates to quantitative molecular indicators that canguide clinical decisions in breast cancer, such as estrogen receptor (ESR1)-positive, lymph node-negative breast cancer. In particular, the inventionconcerns certain genes, the varied expression of which indicates thelikelihood of recurrence of surgically resected breast cancer in patients whoare not treated with a therapeutic agent in the adjuvant setting. In addition,the invention concerns the use of quantitative measurement of the expressionof certain genes, including the ESR1 gene, that measures as a continuousvariable, to determine (a) the likelihood of a beneficial response to the anti-estrogen therapeutic agent, such as tamoxifen; and (b) the potential magnitudeof beneficial response to chemotheraphy.